Diabetes Drug Dapagliflozin May Prevent Fatal Heart Failure in Genetic Risk Group

Research reveals that dapagliflozin, a diabetes drug, could reduce the risk of fatal heart failure in individuals with specific genetic risks. This is significant for health research and potential new treatment avenues. The study's findings could lead to broader applications in cardiovascular health.